The value of a Quality-Adjusted Life Year (QALY) used to screen medicines for inclusion in the National List of Essential Medicines (NLEM) in 2013 was 160,000 baht per QALY. Any medicines that cost less than this amount is considered to be cost-effective. However, is this figure consistent with publ

What do you think about COVID-19 vaccination certificates for international travel? This survey on COVID-19 vaccination certificates is part of a regional research study from the COVID-19 vaccination policy research and decision-support initiative in Asia (CORESIA). We would like

Access to effective and affordable antibiotics remains a major challenge globally, particularly in low- and middle-income countries. To address this, SECURE, a global initiative led by World Health Organisation (WHO) and the Global Antibiotic Research and Development Partnership (GARDP) aims to work with countries to pioneer new approaches to ensur

Introduction: The development of new technology to treat patients with metastatic renal cell carcinoma has resulted in promising outcomes in terms of extending life and improving quality of life. In Thailand, where health resources are limited, an economic evaluation of such technology would provide useful information for pricing and reimbursement

This report summarises the discussion during a meeting held on 30th June 2022 to discuss lessons learned from the RECOVERY Trial and areas of potential collaboration to conduct clinical research in Thailand. This meeting was supported by the National Health Foundation (NHF), the Access and Delivery

A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand. Pattara Leelahavarong1,2, Usa Chaikledkaew1,2*, Suradej Hongeng3, Vijj Kasemsup4, Yoel Lubell1,5, Yot Teerawattananon1 1Health Intervention and Technolog

Reviewing the evidence on effectiveness and cost-effectiveness of HIV prevention strategies in Thailand. Pattanaphesaj J, Teerawattananon Y.  Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Thailand Backgroud: Following universal access to antiretroviral

ROONGNAPA KHAMPANG1,2, SAWITRI ASSANANGKORNCHAI1 & YOT TEERAWATTANANON2 1Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, HatYai, Songkhla, Thailand, and 2Health Intervention and Technology Assessment Program, Department of Health, Ministry of Public Health, Nonthaburi, Tha

Yot Teerawattananon programme leader1, Alia Luz project associate2, Churnrurtai Kanchanachitra director, Mahidol University Global Health 3, Sripen Tantivess senior researcher 1, On behalf of the Prince Mahidol Award Conference secretariat 1Health Intervention and Technology Assessment Program (

Abstract Aim Alcohol related disease conditions are responsible for a significant proportion of morbidity and mortality in Sri Lanka. This study quantified the economic cost of selected alcohol related disease conditions in Sri Lanka in 2015. Methods This study uses the prevalence-based cost